A randomised controlled trial of Standard Of Care versus RadioAblaTion in Early Stage HCC

SOCRATES HCC will investigate whether a radiotherapy technique (called SABR) can treat early stage liver cancer more effectively than current treatments which use heating probes directly inserted into the tumour or chemotherapy or radioactive particles injected into the blood supply of the tumour.

Primary Sponsor

Trans Tasman Radiation Oncology Group (TROG)

Collaborating Groups

Australasian Gastro-Intestinal Trials Group (AGITG), Abdominal Radiology Group of Australia and New Zealand (ARGANZ) & Gastrointestinal Society of Australia (GESA)

Participating Centres

Accrual Target

218

Current Accrual

Trial Chairperson

Prof Alan Wigg, Flinders Medical Centre, SA, Australia

A/Prof David Pryor, Princess Alexandra Hospital, QLD, Australia

Trial Contact

SOCRATES_HCC@trog.com.au

Clinical Trial Registration

Related Post

World Radiotherapy Awareness Day promotion at ESTRO26
10 June, 2026

Global cancer community prepares to unite for 2026 World Radiotherapy Awareness Day

LATEST NEWS: 10 June 2026 The global radiation therapy

4 June, 2026

Report showcases a year of impactful research, collaboration and consumer engagement

LATEST NEWS: 4 June 2025 TROG’s latest Annual Research